[Use of tranexamic acid for bleeding control in myocardial revascularization].
OBJECTIVE
To compare two groups of 80 patients undergoing to myocardial revascularization with the use of antifibrinolytic drug tranexamic acid and its efficacy in reduce bleeding and blood transfusion.


METHODS
Prospective analysis of two groups of 80 patients. Group A-no antifibrinolytic therapy (dec 91-may 92) and group B-fibrinolytic therapy-tranexamic acid-10g EV (jun-dec/92). Quantification of mediastinal drainage over 12h as well as the blood or derivatives received at the same time.


RESULTS
Hospital mortality: group A-3.8%, group B-2.5%. Drainage (12h): group A-602 +/- 547 ml and group B-260 +/- 260 ml (p < 0.001). Blood transfusion (12h): group A-1,782 +/- 1,163 ml and group B-1,105 +/- 839 ml (p < 0.001).


RESULTS
group A-two cases of intraoperative myocardial infarction, one episode of jaundice; group B-one case of intraoperative MI, one reoperation for bleeding control, one episode of jaundice, one of renal insufficiency, two mediastinitis and one seizure. The mean hospitalization time was ten days in both groups.


CONCLUSIONS
Tranexamic acid was an effective drug in bleeding control and in reducing blood transfusion in the postoperative of patients submitted to myocardial revascularization.
Couto
W J
WJ
Faculdade de Medicina, Universidade Estadual de Londrina e Hospital Evangélico.
Gregori Júnior
F
F
Cordeiro
C O
CO
Silva
S S
SS
Ketzer
J L
JL
Silva
L
L
Rosa
V
V
Freitas
M
M
Wanderley
W R
WR
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D016063:Blood Loss, Surgical / Q000517:prevention & control*; D005112:Extracorporeal Circulation / Q000009:adverse effects; D005260:Female; D006488:Hemostasis, Surgical / Q000379:methods*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009204:Myocardial Revascularization / Q000009:adverse effects*; D011446:Prospective Studies; D014148:Tranexamic Acid / Q000009:adverse effects / Q000627:therapeutic use*
D014148:Tranexamic Acid